Skip to main content
SpringerLink
Log in
Book cover

Handbook of Drug Interactions pp 493–596Cite as

Anabolic Doping Agents

  • Chapter

  • 510 Accesses

Part of the book series: Forensic Science and Medicine ((FSM))

Abstract

The desire to gain an upper edge in war and athletic competition can be traced back into antiquity. The early Greeks used hallucinogenic mushrooms and the central nervous system (CNS) stimulant strychnine in order to gain an edge in battle and in Olympic competition. Gladiators were known to use stimulants to stave off fatigue during their gladiatorial battles. During the pre- to early Christian era, the Berserkers, ancient Germanic warriors, were known for their savagery and frenzied rage in battle (1). Modern scholars believe that prior to battle, they would consume hallucinogenic mushrooms (Bufotein from the fungus Amanita muscaria) and/or massive quantities of alcohol. It was not until the end of the 16th century that Europeans learned of caffeinecontaining drugs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hallakarva Gunnora “Berserkergang.” Stefan’s Florilegium Berserkergang-art. http://www.florilegium.org.

  2. Lombardo JA. Anabolic-androgenic steroids. In: Lin GC and Erinoff L, eds. Anabolic steroid abuse. NIDA Research Monograph 102:60–73 (1990).

    Google Scholar 

  3. Times Record News; Wichita Falls, Texas; June 18, 2001. Speed’s long history: amphetamine drugs have caused trouble for decades. Jeff Hall, Times Record News www.trnonline.com/archives/2001archives/06182001/local_news/25530.shtml. Jeff Hall may be contacted at (940)-763–7596 or by e-mail at hallj@wtr.com.

  4. Goodman LS and Gilman A. Goodman and A. Gilman’s The pharmacological basis of therapeuics, 1st ed. New York:McGraw-Hill, 1941:1207–1226.

    Google Scholar 

  5. NIDA report, http://www.nida.nih.gov/ResearchReports/Steroids/anabolicsteroids.htm

  6. World Anti-Doping Agency (WADA), www.wada.org

  7. Kochakian CD. History of anabolic-androgenic steroids. In: Lin GC and Erinoff L, eds. Anabolic steroid abuse. NIDA Research Monograph 102:29–59 (1990).

    Google Scholar 

  8. Burtis CA and Ashwood ER. Tietz’s textbook of clinical chemistry, 2nd ed. Philadelphia: Saunders, 1994:1783–1795, 1843–1856.

    Google Scholar 

  9. Morrison RT and Boyd RN. Organic chemistry, 3rd ed. Boston: Allyn & Bacon, 1974: 115–142, 225–247, 515.

    Google Scholar 

  10. von Deutsch DA, Abukhalaf IK, Aboul-Enein HY, Wineski LE, Oster RA, Paulsen DF, and Potter DE. β3-Agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. Chirality 12:137–148 (2000).

    Google Scholar 

  11. Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD, and Dalton JT. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 26:117–122 (1996).

    CAS  PubMed  Google Scholar 

  12. Budavari S, O’Neil MJ, Smith A, Heckelman PE, and Kinneary JF. The Merck index, An encyclopedia of chemicals, drugs, and biologicals, 12th ed. Whitehouse Station, NY: Merck Research Laboratories Division of Merck & Co., Inc., 1996.

    Google Scholar 

  13. Katzung BG. Basic & clinical pharmacology, 8th ed. New York: McGraw-Hill, 2001:20–137, 138–154, 625–643, 679–710.

    Google Scholar 

  14. Time Report, Dope into Gold, Jan. 19, 1998, vol. 151, No. 3.

    Google Scholar 

  15. Hardman JG and Limbird LE. Goodman and Gilman’s The pharmacological basis of therapeuics, 10th ed. New York: McGraw-Hill, 2001:199–248, 282–284, 1441–1458.

    Google Scholar 

  16. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, and Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site—a clinical research center study. J Clin Endocrinol Metab 81:1832–1840 (1996).

    CAS  PubMed  Google Scholar 

  17. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 85:964–969 (2000).

    CAS  PubMed  Google Scholar 

  18. Zhang GY, Gu YQ, Wang XH, Cui YG, and Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 19:761–768 (1998).

    CAS  PubMed  Google Scholar 

  19. Segura J, Ventura R, and Jurado C. Derivatization procedures for gas chromatographicmass spectrometric determination of xenobiotics in biological samples, with special attention to drugs of abuse and doping agents. matogr. B Biomed Sci Appl 713:61–90 (1998).

    CAS  Google Scholar 

  20. Simionescu L, Neacsu E, Zimel A, and Caragheorgheopol A. The development of a radioimmunoassay system for testosterone (T) and dihydrotestosterone (DHT). Part 2. The preparation of antisera to T. Endocrinologie 28:107–125 (1990).

    CAS  PubMed  Google Scholar 

  21. Peng SH, Segura J, Farre M, Gonzalez JC, and de la Torre X. Plasma and urinary markers of oral testosterone undecanoate misuse. Steroids 67:39–50 (2002).

    CAS  PubMed  Google Scholar 

  22. SmartBodyz Nutrition; http://www.smartbodyz.com; Fort Worth, Texas 76102; Toll Free: 187; SmartBodyz (1–877–627–8263); Telephone: 817–335–1982; E-mail: webmaster@smartbodyz.com

  23. King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, and Parsons KA. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men. JAMA 281:2020–2028 (1999).

    CAS  PubMed  Google Scholar 

  24. Broeder CE, Quindry J, Brittingham K, Panton L, Thomson J, Appakondu S, et al. Physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 160:3093–3104 (2000).

    CAS  PubMed  Google Scholar 

  25. Gold Standard Clinical Pharmacology 2000. http://cpip.gsm.com/

  26. Wang C and Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 87:1462–1466 (2002). Review.

    Google Scholar 

  27. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol 84:122–129 (2000).

    Google Scholar 

  28. Fujisawa K, Tani P, Piro L, and McMillan R. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood 81:2872–2877 (1993).

    CAS  PubMed  Google Scholar 

  29. Otawa M, Kuriyama Y, Iwase O, Kawanishi Y, Miyazawa K, Aizawa S, et al. [Possible role of immunocompetent cells on periodic exacerbation of idiopathic thrombocytopenic purpura]. Rinsho Ketsueki 38:331–335 (1997).

    CAS  PubMed  Google Scholar 

  30. Rittmaster RS, Thompson DL, Listwak S, and Loriaux DL. Androstanediol glucuronide isomers in normal men and women and in men infused with labeled dihydrotestosterone. J Clin Endocrinol Metab 66:212–216 (1988).

    CAS  PubMed  Google Scholar 

  31. Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—a clinical research center study. J Clin Endocrinol Metab 83:2749–2757 (1998).

    CAS  PubMed  Google Scholar 

  32. Kammerer RC, Merdink JL, Jagels M, Catlin DH, and Hui KK. Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry. J Steroid Biochem 36:659–666 (1990).

    CAS  PubMed  Google Scholar 

  33. Capponi VJ, Cox SR, Harrington EL, Wright CE, Antal EJ, and Albert KS. Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. J Pharm Sci 74:308–311 (1985).

    CAS  PubMed  Google Scholar 

  34. Fenichel G, Pestronk A, Florence J, Robison V, and Hemelt V. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 48: 1225–1226 (1997).

    CAS  PubMed  Google Scholar 

  35. Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 56:1075–1107 (2001).

    CAS  PubMed  Google Scholar 

  36. Fox-Wheeler S, Heller L, Salata CM, Kaufman F, Loro ML, Gilsanz V, et al. Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. Pediatrics 104:e73 (1999).

    Google Scholar 

  37. Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenas L, et al. Improved final height in girls with Turner’s syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 81:635–640 (1996).

    CAS  PubMed  Google Scholar 

  38. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, and Dudley R. Oxandrolone in AIDSwasting myopathy. AIDS 10:657–662 (1996).

    Google Scholar 

  39. Guarneri MP, Abusrewil SA, Bemasconi S, Bona G, Cavallo L, Cicognani A, et al. Turner’s syndrome. J Pediatr Endocrinol Metab 14:959–965 (2001).

    PubMed  Google Scholar 

  40. Partsch CJ, Weinbauer GF, Fang R, and Nieschlag E. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol 132:514–519 (1995).

    CAS  PubMed  Google Scholar 

  41. Malan PG and Gould RP. Essentials of endocrinology. O’Riordan JLH, ed. Oxford, England: Blackwell Scientific, 1982:95–98.

    Google Scholar 

  42. Winters SJ. Androgens: endocrine physiology and pharmacology. In: Lin GC and Erinoff L, eds. Anabolic steroid abuse. NIDA Research Monograph 102:113–130 (1990).

    Google Scholar 

  43. Dunn JF, Nisula BC, and Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53:58–68 (1981).

    CAS  PubMed  Google Scholar 

  44. Berendonk B. Doping Dokumente: Von der Forschung zum Betrug. Berlin: Springer-Verlag, 1991:91–171.

    Google Scholar 

  45. East Germany Doping Scandal, wysiwyg://8/ http://abcnews.go.com/...01013_egerman athletes feature.html.

  46. ABCNEWS.com:20/20: East Germany Doping Scandal, wysiwyg://8/ http://abcnews.go.com/...01013_egermanathletes_feature.html.

  47. Palusinski R and Barud W. Effects of androstenedione in young men (Letter to the Editor). JAMA 283:741 (2000).

    CAS  PubMed  Google Scholar 

  48. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, and Finkelstein JS. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 283:779–782 (2000).

    CAS  PubMed  Google Scholar 

  49. Geyer H, Mareck-Engelke U, Reinhart U, Thevis M, and Schänzer W. Positive doping cases with norandrosterone after application of contaminated nutritional supplements [Positive Dopingfälle mit Norandrosteron durch verunreinigte Nahrungsergänzungsmittel]. Deutsche zeitschrift füür sportmedizin 51:378–382 (2000).

    CAS  Google Scholar 

  50. Green GA, Catlin DH, and Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med 11:254–259 (2001).

    CAS  PubMed  Google Scholar 

  51. Tarter RE, Ammerman RT, and Ott Peggy J. Handbook of Substance Abuse: Neurobehavioral Pharmacology. Plenum Press, New York and London, 1998, Chapters 31–34.

    Google Scholar 

  52. Preedy VR, Patel VB, Reilly ME, Richardson PJ, Falkous G, and Mantle D. Oxidants, antioxidants and alcohol: implications for skeletal and cardiac muscle. Front Biosci 4:e58-e66 (1999).

    CAS  PubMed  Google Scholar 

  53. Hoffman RJ, Hoffman RS, Freyberg CL, Poppenga RH, and Nelson LS. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. J Toxicol Clin Toxicol 39:339–344 (2001).

    CAS  PubMed  Google Scholar 

  54. DeRamundo BM and Volpe A. Effect of steroid hormones and antihormones on hypothalamic beta-endorphin concentrations in intact and castrated female rats. J Endocrinol Invest 13:91–96 (1990.)

    PubMed  Google Scholar 

  55. Convertino VA, Polet JL, Engelke KA, Hoffler GW, Lane LD, and Blomqvist CG. Increased beta-adrenergic responsiveness induced by 14 days exposure to simulated microgravity. J Gravit Physiol 2:P66-P67 (1995).

    CAS  PubMed  Google Scholar 

  56. Wines JD Jr, Gruber AJ, Pope HG Jr, and Lukas SE. Nalbuphine hydrochloride dependence in anabolic steroid users. Am J Addict 8:161–164 (1999).

    PubMed  Google Scholar 

  57. von Berg A and Berdel D. [A new beta-2 sympathomimetic drug with longer effectiveness. Comparison with current beta-2 sympathomimetic drugs in therapy of bronchial asthma in childhood]. Monatsschr Kinderheilkd 141:53–58 (1993).

    Google Scholar 

  58. von Deutsch DA, Abukhalaf IK, Wineski LE, Aboul-Enein HY, Potter DE, and Paulsen DF. Distribution and muscle-sparing effects of clenbuterol in hindlimb suspended rats. Pharmacol 65:38–48 (2002).

    Google Scholar 

  59. von Deutsch DA, Abukhalaf IK, Wineski LE, Silvestrov NA, Bayorh M, and Potter DE. Changes in muscle proteins and spermidine content in response to unloading and clenbuterol treatment. C J Physiol Pharmacol 81:28–39 (2003).

    Google Scholar 

  60. Eudra, (European Agency for the Evaluation of Medical Products: Veterinary Medicines and Information Technology Unit); EMEA/MRL/723/99-FINAL Feb 2000. Westferry Circus, 7 Canary Wharf, E14 4HB LONDON, (Tel: +44 207 418–8569 Fax: +44 207 4188416)/ E-mail: mail@emea.eudra.org; http://www.eudra.org/emea.html.

  61. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, and Paulsen DF. Muscle-specific effects of hindlimb suspension and clenbuterol in mature, male rats. Cells Tissues Organs 171:188–198 (2002).

    CAS  PubMed  Google Scholar 

  62. Schmekel B, Rydberg I, Norlander B, Sjosward KN, Ahlner J, and Andersson RG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 13:1230–1235 (1999).

    CAS  PubMed  Google Scholar 

  63. Tryniszewski C. Nurse’s drug looseleaf. Blue Bell, PA: Blanchard & Loeb, 2001.

    Google Scholar 

  64. Morales-Olivas FJ, Brugger AJ, Bedate H, Garcia-Diez JM, Morcillo E, and Esplugues J. [Clenbuterol: a new partial antagonist of the beta adrenergic receptors (author’s trans1)]. Arch Farmacol Toxicol 6:131–138 (1980).

    CAS  PubMed  Google Scholar 

  65. Perez R, Garcia M, Arias P, Gallardo M, Valenzuela S, and Rudolph MI. Inhibition of xylazine induced uterine contractility by clenbuterol and nifedipine. Res Vet Sci 63:73–76 (1997).

    CAS  PubMed  Google Scholar 

  66. Stegmann GF and Bester L. Some cardiopulmonary effects of midazolam premedication in clenbuterol-treated bitches during surgical endoscopic examination of the uterus and ovariohysterectomy. J S Afr Vet Assoc 72:33–76 (2001).

    CAS  PubMed  Google Scholar 

  67. Maltin CA, Delday MI, Hay SM, lnnes GM, and Williams PE. Effects of bovine pituitary growth hormone alone or in combination with the beta-agonist clenbuterol on muscle growth and composition in veal calves. Br J Nutr 63:535–545 (1990).

    CAS  PubMed  Google Scholar 

  68. Smith DJ. The pharmacokinetics, metabolism, and tissue residues of beta-adrenergic agonists in livestock. J Anim Sci 76:173–194 (1998).

    CAS  PubMed  Google Scholar 

  69. Maltin CA, Delday MI, Watson JS, Heys SD, Nevison IM, Ritchie IK, and Gibson PH. Clenbuterol, a β3-adrenoreceptor agonist, increases relative muscle strength in orthopedic patients. Clin Sci 84:651–654 (1993).

    CAS  PubMed  Google Scholar 

  70. Bates PC and Pell JM. Action and interaction of growth hormone and the beta-agonist, clenbuterol, on growth, body composition and protein turnover in dwarf mice. Br J Nutr 65: 115–129 (1991).

    CAS  PubMed  Google Scholar 

  71. Reeds PJ, Hay SM, Dorwood PM, and Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 56:249–258 (1986).

    CAS  PubMed  Google Scholar 

  72. Reichel K, Rehfeldt C, Weikard R, Schadereit R, and Krawielitzki K. [Effect of a betaagonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats]. Arch Tierernahr 45:211–225 (1993).

    CAS  PubMed  Google Scholar 

  73. Abukhalaf IK, von Deutsch DA, Wineski LE, Silvestrov NA, Abera SA, Sahlu SW, and Potter DE. Effect of hindlimb suspension and clenbuterol treatment on polyamine levels in skeletal muscle. Pharmacol 65:145–154 (2002).

    CAS  Google Scholar 

  74. Apseloff G, Girten B, Walker M, Shepard DR, Krecic ME, Stern LS, and Gerber N. Aminohydroxybutane bisphosphonate and clenbuterol prevent bone changes and retard muscle atrophy respectively in tail-suspended rats. J Pharmacol Exp Therap 264:1071–1078 (1993).

    CAS  Google Scholar 

  75. Spealman RD. Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 275:53–62 (1995).

    CAS  PubMed  Google Scholar 

  76. Girten B, Oloff C, Plato P, Eveland E, Merola AJ, and Kazarian L. Skeletal muscle antioxidant enzyme levels in rats after simulated weightlessness, exercise and dobutamine. Physiologist 32(Suppl 1):S59-S60 (1989).

    CAS  PubMed  Google Scholar 

  77. Bloomfield SA, Girten BE, and Weisbrode SE. Effects of vigorous exercise training and beta-agonist administration on bone response to hindlimb suspension. J Appl Physiol 83: 172–178 (1997).

    CAS  PubMed  Google Scholar 

  78. Desplanches D, Favier R, Sempore B, and Hoppeler H. Whole body and muscle respiratory capacity with dobutamine and hindlimb suspension. J Appl Physiol 71:2419–2424 (1991).

    CAS  PubMed  Google Scholar 

  79. Takeo S, Elmoselhi AB, Goel R, Sentex E, Wang J, and Dhalla NS. Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil. Mol Cell Biochem 213:111–118 (2000).

    CAS  PubMed  Google Scholar 

  80. Katz I, Lloyd T, and Kaufman S. Studies on phenylalanine and tyrosine hydroxylation by rat brain tyrosine hydroxylase. Biochim Biophys Acta 445:567–578 (1976).

    CAS  PubMed  Google Scholar 

  81. Fitzpatrick PF. The aromatic amino acid hydroxylases. Adv Enzymol Relat Areas Mol Biol 74:235–294 (2000).

    CAS  PubMed  Google Scholar 

  82. Siegel GJ, Albers RW, Alganoff BW, and Katzman R. Basic neurochemistry, 3rd ed. Boston: Little, Brown, 1981:205–218.

    Google Scholar 

  83. Hardin AO and Lima JJ. Beta 2-Adrenoceptor agonist-induced down-regulation after short-term exposure. J Recept Signal Transduct Res 19:835–852 (1999).

    CAS  PubMed  Google Scholar 

  84. Cepero M, Cubria JC, Reguera R, Balana-Fouce R, Ordonez C, and Ordonez D. Plasma and muscle polyamine levels in aerobically exercised rats treated with salbutamol. Pharm Pharmacol 50:1059–1064 (1998).

    CAS  Google Scholar 

  85. Genazzani AR, Petraglia F, Mercuri N, Brilli G, Genazzani AD, Bergamaschi M, et al. Effect of steroid hormones and antihormones on hypothalamic beta-endorphin concentrations in intact and castrated female rats. J Endocrinol Invest 13:91–96 (1990).

    CAS  PubMed  Google Scholar 

  86. Cepero M, Perez-Pertejo Y, Cubria JC, Reguera R, Balana-Fouce R, Ordonez C, et al. Muscle and serum changes with salbutamol administration in aerobically exercised rats. Comp Biochem Physiol C Toxicol Pharmacol 126:45–51 (2000).

    CAS  PubMed  Google Scholar 

  87. Cubria JC, Ordonez C, Reguera RM, Tekwani BL, Balana-Fouce R, and Ordonez D. Early alterations of polyamine metabolism induced after acute administration of clenbuterol in mouse heart. Life Sci 64:1739–1752 (1999).

    CAS  PubMed  Google Scholar 

  88. Turchanowa L, Rogozkin VA, Milovic V, Feldkoren BI, Caspary WF, and Stein J. Influence of physical exercise on polyamine synthesis in the rat skeletal muscle. Eur J Clin Invest 30:72–78 (2000).

    CAS  PubMed  Google Scholar 

  89. http://www.cyberflex.co.uk/steroidcyclofenil.htm

  90. Lewis MI, LoRusso TJ, and Fournier M. Anabolic influences of insulin-like growth factor I and/or growth hormone on the diaphragm of young rats. J Appl Physiol 82:1972–1978 (1997).

    CAS  PubMed  Google Scholar 

  91. Wong JM, Forrest KA, Snabes SZ, Zhao SZ, Gersh GE, and Kennedy SH. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Hum Reprod Update 7:92–101 (2001).

    CAS  PubMed  Google Scholar 

  92. www.achilleshealthmart.com

  93. Ishii I and Kitada M. [Multidrug-resistance by induction of inactivation for anticancer drugs]. Nippon Rinsho 55:1044–1049 (1997).

    CAS  PubMed  Google Scholar 

  94. Waddle JR, Fine RL, Case BC, Trogdon ML, Tyczkowska K, Frazier D, and Page RL. Phase I and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs. Cancer Chemother Pharmacol 44:74–80 (1999).

    CAS  PubMed  Google Scholar 

  95. Lidstrom P, Bonasera TA, Kirilovas D, Lindblom B, Lu L, Bergstrom E, et al. Synthesis, in vivo rhesus monkey biodistribution and in vitro evaluation of a 11C-labelled potent aromatase inhibitor: [N-methyl-11C]vorozole. Nucl Med Biol 25:497–501 (1998).

    CAS  PubMed  Google Scholar 

  96. Piotrovsky VK, Huang ML, Van Peer A, and Langenaecken C. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Cancer Chemother Pharmacol 42:221–228 (1998).

    CAS  PubMed  Google Scholar 

  97. Alshowaier IA, el-Yazigi A, Ezzat A, Abd el-Warith A, and Nicholls PJ. Pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients. J Clin Pharmacol 39:1136–1142 (1999).

    CAS  PubMed  Google Scholar 

  98. Goss PE. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast Cancer Res Treat 49(Suppl 1):S59-S65; discussion S73-S77 (1998).

    Google Scholar 

  99. Wiseman LR and Spencer CM. Vorozole. Drugs Aging 11:245–250; discussion 251–252 (1997).

    CAS  PubMed  Google Scholar 

  100. van de Kerkhof DH, de Boer D, Thijssen JH, and Maes RA. Evaluation of testosterone/ epitestosterone ratio influential factors as determined in doping analysis. J Anal Toxicol 24:102–115 (2000).

    Google Scholar 

  101. Kjeld JM, Puah CM, and Joplin GF. Rise of unconjugated sex hormones in human urine on storage. Clin Chim Acta 80:285–291 (1977).

    CAS  PubMed  Google Scholar 

  102. Kjeld JM, Puah CM, and Joplin GF. Labile testosterone conjugate in human urine: further evidence. Clin Chim Acta 93:227–233 (1979.)

    PubMed  Google Scholar 

  103. Rantonen PJ, Penttila I, Meurman JH, Savolainen K, Narvanen S, Helenius T. Growth hormone and cortisol in serum and saliva. Acta Odontol Scand 58:299–303 (2000),

    CAS  PubMed  Google Scholar 

  104. Vapaatalo H, Karkainen S, and Senius KE. Comparison of saliva and urine samples in thin-layer chromatographic detection of central nervous stimulants. Int J Clin Pharmacol Res 4:5–8 (1984).

    CAS  PubMed  Google Scholar 

  105. Hofman LF. Human saliva as a diagnostic specimen. J Nutr 131:1621S-1625S (2001).

    CAS  PubMed  Google Scholar 

  106. Gaillard Y, Vayssette F, and Pepin G. Compared interest between hair analysis and urinalysis in doping controls. Results for amphetamines, corticosteroids and anabolic steroids in racing cyclists. Forensic Sci Int 107:361–379 (2000).

    CAS  PubMed  Google Scholar 

  107. Dumestre-Toulet V, Cirimele V, Ludes B, Gromb S, and Kintz P. Hair analysis of seven bodybuilders for anabolic steroids, ephedrine, and clenbuterol. J Forensic Sci 47:211–214 (2002).

    CAS  PubMed  Google Scholar 

  108. Kintz P, Cirimele V, Sachs H, Jeanneau T, and Ludes B. Testing for anabolic steroids in hair from two bodybuilders. Forensic Sci Int 101:209–216 (1999).

    CAS  PubMed  Google Scholar 

  109. Kintz P, Cirimele V, Dumestre-Toulet V, Villain M, and Ludes B. Doping control for methenolone using hair analysis by gas chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 766:161–167 (2002).

    CAS  PubMed  Google Scholar 

  110. Abukhalaf IK, von Deutsch DA, Parks BA, Wineski LE, Paulsen DF, Abul-Enein HY, and Potter DE. Comparative analytical quantitation of clenbuterol in biological matrices using GC-MS and EIA. Biomed Chromatogr 14:99–105 (2000).

    CAS  PubMed  Google Scholar 

  111. Hammond GL, Ruokonen A, Kontturi M, Koskela E, and Vihko R. The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. J Clin Endocrinol Metab 45:16–24 (1977).

    CAS  PubMed  Google Scholar 

  112. Harper JM, Mackinson I, and Buttery PJ. The effects of beta agonists on muscle cells in culture. Domest Anim Endocrinol 7:477–484 (1990).

    CAS  PubMed  Google Scholar 

  113. Konishi H, Minouchi T, and Yamaji A. Interference by danazol with the Porter-Silber method for determination of urinary 17-hydroxycorticosteroids. Ann Clin Biochem 38: 277–279 (2001).

    CAS  PubMed  Google Scholar 

Additional Reading

  • Akahane K, Furukawa Y, Ogiwara Y, Haniuda M, and Chiba S. Beta-adrenoceptor blocking effects of a selective beta 2-agonist, mabuterol, on the isolated, blood-perfused right atrium of the dog. Br J Pharmacol 97:709–716 (1989).

    CAS  PubMed  Google Scholar 

  • Amemiya K, Kudoh M, Suzuki H, Saga K, and Hosaka K. Toxicology of mabuterol. Arzneimittelforschung 34:1680–1684 (1984).

    CAS  PubMed  Google Scholar 

  • Amemiya K, Asano T, Arika T, Nakamura M, and Kudoh M. Special toxicology-physical dependence potential, antigenicity and mutagenicity of mabuterol. Arzneimittelforschung 34: 1685–1686 (1984).

    CAS  PubMed  Google Scholar 

  • Baronti A, Lelli M, Manini G, and Verdiani P. Procaterol metered aerosol in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Res 7:363–368 (1987).

    CAS  PubMed  Google Scholar 

  • Baselt RC and Cravey RH. Disposition of toxic drugs and chemical in man, 4th ed. Foster City, CA: Chemical Toxicology Institute 1995:1, 7, 16, 44, 76, 108, 186, 222, 293, 405, 407, 448, 476, 478, 686, 693, 703, 720.

    Google Scholar 

  • Beastall GH, Ratcliffe WA, Thomson M, and Semple CG. Trilostane interference with steroid assays. Lancet 1:727–728 (1981).

    CAS  PubMed  Google Scholar 

  • Bowers LD. Analytical advances in detection of performance-enhancing compounds. Clin Chem 43:1299–1304 (1997).

    CAS  PubMed  Google Scholar 

  • Brambilla G, Cenci T, Franconi F, Galarini R, Macri A, Rondoni F, et al. Clinical and pharmacological profile in a clenbuterol epidemic poisoning of contaminated beef meat in Italy. Toxicol Lett 114:47–53 (2000).

    CAS  PubMed  Google Scholar 

  • Brasch J and Flader S. Human androgenic steroids affect growth of dermatophytes in vitro. Mycoses 39:387–392 (1996).

    PubMed  Google Scholar 

  • Brown J, Clasper C, Smith T, and Lomax MA. Effects of a beta 2-adrenergic agonist, cimaterol and corticosterone on growth and carcass composition of male rats. Comp Biochem Physiol 102:217–220 (1992).

    CAS  Google Scholar 

  • Byrem TM, Beermann DH, and Robinson TF. The beta-agonist cimaterol directly enhances chronic protein accretion in skeletal muscle. J Anim Sci 76:988–998 (1998).

    CAS  PubMed  Google Scholar 

  • Byrem TM, Robinson TF, Boisclair YR, Bell AW, Schwark WS, and Beermann DH. Analysis and pharmacokinetics of cimaterol in growing Holstein steers. J Anim Sci 70:3812–3819 (1992).

    CAS  PubMed  Google Scholar 

  • Cardoso LA and Stock MJ. Effect of clenbuterol on growth and body composition during food restriction in rats. J Anim Sci 74:2245–2252 (1996).

    CAS  PubMed  Google Scholar 

  • Chance WT, Zhang X, Zuo L, and Balasubramaniam A. Reduction of gut hypoplasia and cachexia in tumor-bearing rats maintained on total parenteral nutrition and treated with peptide YY and clenbuterol. Nutrition 14:502–507 (1998).

    CAS  PubMed  Google Scholar 

  • Chikhou F, Moloney AP, Austin FH, Roche JF, and Enright WJ. Effects of cimaterol administration on plasma concentrations of various hormones and metabolites in Friesian steers. Domest Anim Endocrinol 8:471–480 (1991).

    CAS  PubMed  Google Scholar 

  • Dawson R. Editorial, BMC News, 2000.

    Google Scholar 

  • Eisen EJ, Croom WJ Jr, and Helton SW. Differential response to the beta-adrenergic agonist cimaterol in mice selected for rapid gain and unselected controls. Anim Sci 66:361–371 1988.

    CAS  Google Scholar 

  • Fischer W, Lasek R, and Muller M. Anticonvulsant effects of propranolol and their pharmacological modulation. Pol J Pharmacol Pharm 37:883–896 (1985).

    CAS  PubMed  Google Scholar 

  • Galan Martin AM, Marino JI, Garcia de Tiedra MP, Marabe JJ, Caballero Loscos MJ, and Marino MM. Determination of nandrolone and metabolites in urine samples from sedentary persons and sportsmen. J Chromatogr B Biomed Sci Appl 761:229–236 (2001).

    Google Scholar 

  • Germouty J, Aubert J, Clavier J, Paramelle B, and Voisin C. [Long-term tolerability of formoterol in chronic obstructive bronchopathies]. Allerg Immunol (Paris) 24:342–347 (1992).

    CAS  Google Scholar 

  • Gleixner A, Sauerwein H, and Meyer HH. Probenecid, sulfinpyrazone and pyrazinamide do not inhibit urinary excretion of the beta 2-adrenoceptor agonist clenbuterol in cattle. Food Addit Contam 13:603–608 (1996).

    CAS  PubMed  Google Scholar 

  • Gleixner A. Probenecid markedly reduces urinary excretion of ethinylestradiol and trimethoprim slightly reduces urinary excretion of clenbuterol. Food Addit Contam 15:415–420 (1998).

    CAS  PubMed  Google Scholar 

  • Grassi V, Daniotti S, Schiassi M, Dottorini M, and Tantucci C. Oral beta 2-selective adrenergic bronchodilators. Int J Clin Pharmacol Res 6:93–103 (1986).

    CAS  PubMed  Google Scholar 

  • Gregorevic P, Williams DA, and Lynch GS. Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol. Muscle Nerve 25:194–201 (2002).

    CAS  PubMed  Google Scholar 

  • Groot MJ, Schilt R, Ossenkoppele JS, Berende PL, and Haasnoot W. Combinations of growth promoters in veal calves: consequences for screening and confirmation methods. Zentralbl Veterinarmed A 45:425–440 (1998).

    CAS  PubMed  Google Scholar 

  • Guentert TW, Buskin JN, and Galeazzi RL. Single dose pharmacokinetics of mabuterol in man. Arzneimittelforschung 34:1691–1696 (1984).

    CAS  PubMed  Google Scholar 

  • Hamada K, Kihana T, Kataoka M, Yoshioka S, Nishio S, Matsuura S, and Ito M. Urinary disturbance after therapy for cervical cancer: urodynamic evaluation and beta2-agonist medication. Int Urogynecol J Pelvic Floor Dysfunct 10:365–370 (1999).

    CAS  PubMed  Google Scholar 

  • Harri M. Beta blockade and physical training in rats. Ann Clin Res 14(Suppl 34):168–172 (1982).

    PubMed  Google Scholar 

  • Hernandez-Carrasquilla M. External contamination of bovine hair with beta2-agonist compounds: evaluation of decontamination strategies. J Chromatogr B Biomed Sci Appl 767: 235–243 (2002).

    CAS  Google Scholar 

  • Horiba M, Murai T, Nomura K, Yuge T, Sanai K, and Osada E. Pharmacokinetic studies of mabuterol, a new selective beta 2-stimulant. II: urinary metabolites of mabuterol in rats and their pharmacological effects. Arzneimittelforschung 34:1668–1679 (1984).

    CAS  PubMed  Google Scholar 

  • Huang H, Gazzola C, Pegg GG, and Sillence MN. Differential effects of dexamethasone and clenbuterol on rat growth and on beta2-adrenoceptors in lung and skeletal muscle. J Anim Sci 78:604–608 (2000).

    CAS  PubMed  Google Scholar 

  • Hunt DG, Ding Z, and Ivy JL. Clenbuterol prevents epinephrine from antagonizing insulinstimulated muscle glucose uptake. J Appl Physiol 92:1285–1292 (2002).

    CAS  PubMed  Google Scholar 

  • Ishizaki O, Daidohji S, Kimura K, Shibuya K, Horiguchi T, and Sekiwa M. Reproduction studies with mabuterol in rats. Arzneimittelforschung 34:1687–1690 (1984).

    CAS  PubMed  Google Scholar 

  • Kawakami Y. First clinical studies on mabuterol. A summarizing report. Arzneimittelforschung 34:1699–1700 (1984).

    CAS  PubMed  Google Scholar 

  • Kazlauskas R and Trout G. Drugs in sports: analytical trends. Ther Drug Monit 22:103–109 (2000).

    CAS  PubMed  Google Scholar 

  • Kim J, Shigetomi S, Tanaka K, Yamada ZO, Hashimoto S, and Fukuchi S. [The role of beta 2adrenoceptor on the pathogenesis of insulin resistance in essential hypertension]. Nippon Naibunpi Gakkai Zasshi 70:521–528 (1994).

    CAS  PubMed  Google Scholar 

  • Lacey RJ, Cable HC, James RF, London NJ, Scarpello JH, and Morgan NG. Concentrationdependent effects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans. J Endocrinol 138:555–563 (1993).

    CAS  PubMed  Google Scholar 

  • Lavoie JL, Calderone A, and Beliveau L. A farnesyltransferase inhibitor attenuated beta-adrenergic receptor down regulation in rat skeletal muscle. Am J Physiol Regul Integr Comp Physiol 282:R317–R322 (2002).

    CAS  PubMed  Google Scholar 

  • Le Bizec B, Bryand F, Gaudin I, Monteau F, Poulain F, and Andre F. Endogenous nandrolone metabolites in human urine: preliminary results to discriminate between endogenous and exogenous origin. Steroids 67:105–110 (2002).

    PubMed  Google Scholar 

  • Lepage N, Roberts KD, and Langlais J. Interference of lysophosphatidylcholine in hormone radioimmunoassays. Clin Chem 39:865–869 (1993).

    CAS  PubMed  Google Scholar 

  • Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 15:213–228 (1986).

    CAS  PubMed  Google Scholar 

  • Matsumoto K, Ojima K, Ohta H, and Watanabe H. Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav 49:13–18 (1994).

    CAS  PubMed  Google Scholar 

  • McEvoy JD, McCaughey WJ, Cooper J, Kennedy DG, and McCartan BM. Nortestosterone is not a naturally occurring compound in male cattle. Vet Q 21:8–15 (1999).

    CAS  PubMed  Google Scholar 

  • Merck Manual. http://www.merck.com/pubs/mmanual/section22/chapter305/305a.htm

  • Miyata T, Kai H, Furusawa K, Nakamura H, Saito M, Okano Y, and Takahama K. Secretomotor and mucolytic effects of mabuterol, a novel bronchodilator. Arch Int Pharmacodyn Ther 288:147–160 (1987).

    CAS  PubMed  Google Scholar 

  • Mueller RK, Grosse J, Lang R, and Thieme D. Chromatographic techniques—the basis of doping control. J Chromatogr B Biomed Appl 674:1–11 (1995).

    CAS  PubMed  Google Scholar 

  • Murakami K, Nakagawa T, Yamashiro G, Araki K, and Akasofu K. Adrenal steroids in serum during danazol therapy, taking into account cross-reactions between danazol metabolites and serum androgens. Endocr J 40:659–664 (1993).

    CAS  PubMed  Google Scholar 

  • Murtha PE, Zhu W, Zhang J, Zhang S, and Young CY. Effects of Ca++ mobilization on expression of androgen-regulated genes: interference with androgen receptor-mediated transactivation by AP-I proteins. Prostate 33:264–270 (1997).

    CAS  PubMed  Google Scholar 

  • Nakamura M, Yamaya M, Fukushima T, Sekizawa K, Sasaki H, and Takishima T. Effect of mabuterol on tracheal mucociliary clearance of magnetized iron particles in anesthetized dogs. Respiration 58:33–36 (1991).

    CAS  PubMed  Google Scholar 

  • Nielen MW, Vissers JP, Fuchs RE, van Velde JW, and Lommen A. Screening for anabolic steroids and related compounds in illegal cocktails by liquid chromatography/time-of-flight mass spectrometry and liquid chromatography/quadrupole time-of-flight tandem mass spectrometry with accurate mass measurement. Rapid Commun Mass Spectrom 15:1577–1585 (2001).

    CAS  PubMed  Google Scholar 

  • O’Connor RM, Butler WR, Finnerty KD, Hogue DE, and Beermann DH. Acute and chronic hormone and metabolite changes in lambs fed the beta-agonist, cimaterol. Domest Anim Endocrinol 8:537–548 (1991).

    PubMed  Google Scholar 

  • Puls I, Beck M, Giess R, Magnus T, Ochs G, and Toyka KV. [Clenbuterol in amyotrophic lateral sclerosis. No indication for a positive effect]. Nervenarzt 70:1112–1115 (1999).

    CAS  PubMed  Google Scholar 

  • Ramos F, Castilho MC, and Silveira MI. Occurrence of beta 2-adrenergic agonist residues in urine of animal meat producers in Portugal. J AOAC Int 81:544–548 (1998).

    CAS  PubMed  Google Scholar 

  • Sainz RD and Wolff JE. Effects of the beta-agonist, cimaterol, on growth, body composition and energy expenditure in rats. Br J Nutr 60:85–90 (1988).

    CAS  PubMed  Google Scholar 

  • Saugy M, Cardis C, Robinson N, and Schweizer C. Test methods: anabolics. Baillieres Best Pract Res Clin Endocrinol Metab 14:111–133 (2000).

    CAS  PubMed  Google Scholar 

  • Schmidt EW, Ulmer WT, and Rominger KL. Pharmacokinetics and pharmacodynamics of beta 2-agonists (in the light of fenoterol). Respiration 62:190–200 (1995).

    CAS  PubMed  Google Scholar 

  • Shinohara Y and Baba S. Stable isotope methodology in the pharmacokinetic studies of androgenic steroids in humans. Steroids 55:170–176 (1990).

    CAS  PubMed  Google Scholar 

  • Simon M and Babich-Armstrong M. 17-Hydroxycorticosteroids in urine. Clin Chim Acta 103: 101–108 (1980).

    CAS  PubMed  Google Scholar 

  • Stallion A, Zhang FS, Chance WT, Foley-Nelson T, and Fischer JE. Reversal of cancer cachexia in rats by cimaterol and supplemental nutrition. Surgery 110:678–684 (1991).

    CAS  PubMed  Google Scholar 

  • Taguchi S, Yoshida S, Tanaka Y, and Hori S. [Simple and rapid analysis of trenbolone and zeranol residues in cattle muscle and liver by stack-cartridge solid-phase extraction and HPLC using on-line clean-up with EC and UV detection]. Shokuhin Eiseigaku Zasshi 42: 226–230 (2001).

    CAS  PubMed  Google Scholar 

  • Thomas DP, McCormick KM, and Jenkins RR. Effects of beta-adrenergic blockade on training-induced structural adaptations in rat left ventricle. Eur J Appl Physiol Occup Physiol 57:671–676 (1988).

    CAS  PubMed  Google Scholar 

  • Touchstone JC. Steroids. In: Zweig G and Sherma J, eds. Handbook of chromatography. Boca Raton, FL: CRC Press, 1986:3–25, 41–64.

    Google Scholar 

  • Walker HC and Romsos DR. Effects of cimaterol, a beta-adrenergic agonist, on energy metabolism in ob/ob mice. Am J Physiol 255:R952–R960 (1988).

    CAS  PubMed  Google Scholar 

  • Wu AH. Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse. Ann Clin Lab Sci 25:319–329 (1995).

    CAS  PubMed  Google Scholar 

  • Yen JT, Mersmann HJ, Nienaber JA, Hill DA, and Pond WG. Responses to cimaterol in genetically obese and lean pigs. J Anim Sci 68:2698–2706 (1990).

    CAS  PubMed  Google Scholar 

  • Yoon JM and Lee KH. Gas chromatographic and mass spectrometric analysis of conjugated steroids in urine. J Biosci 26:627–634 (2001).

    CAS  PubMed  Google Scholar 

  • Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, et al. Inhibition of tumor necrosis factor-alpha and interleukin- 1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacol 54:144–152 (1997).

    CAS  Google Scholar 

Websites

Download references

Authors
  1. Daniel A. von Deutsch DDS, PhD, MSCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Imad K. Abukhalaf PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robin R. Socci PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harris County Medical Examiner Office, Houston, TX, USA

    Ashraf Mozayani PharmD, PhD

  2. University of Miami School of Medicine, Miami, FL, USA

    Lionel P. Raymon PharmD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

von Deutsch, D.A., Abukhalaf, I.K., Socci, R.R. (2004). Anabolic Doping Agents. In: Mozayani, A., Raymon, L.P. (eds) Handbook of Drug Interactions. Forensic Science and Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-654-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-654-6_14

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-424-1

  • Online ISBN: 978-1-59259-654-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation